Cyclopharm Expands US Strategy With New Order, Contract; Shares Up 4%

MT Newswires Live
02/19

Cyclopharm (ASX:CYC) secured a purchase order from the National Institutes of Health and a contract with Texas Health Presbyterian Hospital Dallas, part of Texas Health Resources, according to a Thursday Australian bourse filing.

The company has installed its core radiopharmaceutical product, Technegas, at two sites within the St. Charles Health System, marking its first implementation in the Pacific Northwest, the filing said.

The company's shares jumped almost 4% in recent Thursday trade.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10